The pharmaceutical industry is at a transformational moment. The financial returns once realized will be tougher to repeat. With fewer FDA approvals, diminishing pipelines, and a decaying blockbuster business model, the imperative to adopt new growth strategies is paramount.
But for large pharma companies, there’s a host of questions about what these future growth strategies should be.
Original Article: Life Science Leader
